Analysts Set Agilent Technologies, Inc. (NYSE:A) Target Price at $161.64

Agilent Technologies, Inc. (NYSE:A – Get Rating) has been assigned a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $161.64.

Several analysts have issued reports on A shares. Barclays initiated coverage on shares of Agilent Technologies in a report on Thursday, May 11th. They issued an “equal weight” rating and a $140.00 price target on the stock. StockNews.com started coverage on Agilent Technologies in a research report on Thursday, May 18th. They set a “buy” rating for the company. Robert W. Baird upped their price objective on Agilent Technologies from $170.00 to $174.00 and gave the company an “outperform” rating in a research report on Wednesday, March 1st. Finally, Credit Suisse Group lifted their price objective on Agilent Technologies from $165.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 1st.

Agilent Technologies Stock Up 0.2 %

A opened at $129.09 on Friday. The business has a 50 day simple moving average of $134.33 and a 200-day simple moving average of $144.32. Agilent Technologies has a 12 month low of $112.52 and a 12 month high of $160.26. The stock has a market capitalization of $38.17 billion, a P/E ratio of 29.14, a P/E/G ratio of 1.89 and a beta of 1.03. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.11 and a quick ratio of 1.53.

Agilent Technologies (NYSE:A – Get Rating) last announced its quarterly earnings results on Tuesday, February 28th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.06. Agilent Technologies had a net margin of 19.09% and a return on equity of 30.35%. The business had revenue of $1.76 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter last year, the firm posted $1.21 EPS. The business’s revenue was up 4.9% compared to the same quarter last year. On average, equities analysts anticipate that Agilent Technologies will post 5.68 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 26th. Investors of record on Monday, July 3rd will be paid a dividend of $0.225 per share. This represents a $0.90 annualized dividend and a yield of 0.70%. The ex-dividend date of this dividend is Friday, June 30th. Agilent Technologies’s dividend payout ratio (DPR) is 20.32%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Delta Asset Management LLC TN acquired a new position in Agilent Technologies during the 4th quarter worth $26,000. Money Concepts Capital Corp acquired a new position in Agilent Technologies in the fourth quarter worth about $26,000. Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. bought a new stake in Agilent Technologies in the fourth quarter valued at about $27,000. Newbridge Financial Services Group Inc. raised its stake in Agilent Technologies by 217.6% during the fourth quarter. Newbridge Financial Services Group Inc. now owns 216 shares of the medical research company’s stock valued at $32,000 after buying an additional 148 shares in the last quarter. Finally, Ancora Advisors LLC bought a new position in Agilent Technologies during the 4th quarter worth approximately $34,000.

Agilent Technologies Company Profile

(Get Rating)

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.